Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07270601 · ClinicalTrials.gov registry record · NA

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

A NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and NAFLD - Non-Alcoholic Fatty Liver Disease, sponsored by ContextVision AB.

Recruiting
Registry status
NA
Development phase
110
Enrollment target
1
Study location

NCT07270601: Recruiting NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and NAFLD - Non-Alcoholic Fatty Liver Disease, sponsored by ContextVision AB.

NCT07270601 is a NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and NAFLD - Non-Alcoholic Fatty Liver Disease that is actively recruiting participants, run by ContextVision AB. The registered enrollment target is 110 participants, above the 83-participant average among 5 other MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07270601, a NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and NAFLD - Non-Alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by ContextVision AB.

RECRUITING
Registry status
NA
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.

Primary Outcome

Clinical qualification of the multiparametric ultrasound-derived fat fraction, defined as its agreement with the established clinical reference, MRI proton density fat fraction (MRI-PDFF) expressed as absolute percentage, in bench testing analysis.

Conditions Studied

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease NAFLD - Non-Alcoholic Fatty Liver Disease

Interventions

  • DEVICE Verasonics NXT Data Acquisition System
  • DEVICE Philips EPIQ Elite
  • DEVICE EchoSense FibroScan
  • DEVICE Philips 3T Ingenia Elition

Study Locations (1)

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2025-11-17
Est. Completion 2026-12-31
Phase NA
ContextVision AB

1 total trials

What NCT07270601 shows while recruiting

NCT07270601 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 5 other MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trials with a reported enrollment target (33% higher).

The record links to 2 conditions, with MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease appearing as the primary indexed condition, and to 4 interventions - of which Verasonics NXT Data Acquisition System is the first listed.

NCT07270601 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT07270601 about?

NCT07270601 is a clinical study titled "Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis". The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expens...

What is the current status of trial NCT07270601?

This trial is currently recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2025-11-17. Estimated completion is 2026-12-31.

What conditions does trial NCT07270601 study?

This clinical trial studies the following conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease.

What interventions are being tested in trial NCT07270601?

The interventions under investigation include: Verasonics NXT Data Acquisition System (DEVICE), Philips EPIQ Elite (DEVICE), EchoSense FibroScan (DEVICE), Philips 3T Ingenia Elition (DEVICE).

Who is sponsoring clinical trial NCT07270601?

This trial is sponsored by ContextVision AB, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07270601 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07270601

Source: ClinicalTrials.gov NCT07270601, the US trial registry maintained by the National Library of Medicine. NCT07270601 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.